Minimal residual disease analysis in myeloma–when, why and where

Uday Yanamandra, Shaji K. Kumar

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


The primary hurdle in the path to curing multiple myeloma (MM) is defining a validated minimal residual disease (MRD) and its utility in the therapeutic decision making. A better definition of MRD will aid in tailoring MM therapy further to address the clonal heterogeneity and genomic instability and overcome patient’s ineffective immune surveillance. MRD analysis can define the logical endpoint for maintenance therapy, in addition also aids in providing a better clinical end point for studies comparing novel agents in myeloma. MRD is a surrogate for the survival in MM. Guidelines for global incorporation of MRD in myeloma are fraught with lack of standardization, universal availability and abridged physicians’ understanding of MRD modalities. We aimed at addressing some of the frequently asked questions in the MRD assessment and will also place in perspective some arguments in favor of MRD assessment in routine practice and clinical trial scenario.

Original languageEnglish (US)
Pages (from-to)1772-1784
Number of pages13
JournalLeukemia and Lymphoma
Issue number8
StatePublished - Aug 3 2018


  • Multiple myeloma
  • flow cytometry
  • imaging
  • residual disease
  • response
  • sequencing
  • survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Minimal residual disease analysis in myeloma–when, why and where'. Together they form a unique fingerprint.

Cite this